TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06681116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: structured nano-water
Description: Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ordinary bottled drinking water
Description: Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
Study: NCT01897987

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT04638400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Simvastatin administered daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Ezetimibe administered daily for 6 weeks
Study: NCT04283370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Rehabilitation Program
Description: It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Health program
Description: It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
Study: NCT06702930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning high-intensity interval exercise
Description: High-intensity interval exercise was performed between 8-10 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening high-intensity interval exercise
Description: High-intensity interval exercise was performed between 5-7 pm
Study: NCT04070144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQ-Tip(tm) system
Description: Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
Study: NCT02207023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Training Program
Description: Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
Study: NCT04046198

Intervention type: OTHER
Group type: OTHER
Intervention: Educational program
Description: The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
Study: NCT04314154

Intervention type: OTHER
Intervention: Monitoring PROM @ PREM data on participating patients
Description: 125 patients (ages 18-55) admitted to SHALVATA mental health center and their clinicians will be recruited to participate in a prospective longitudinal assessment. Each will include PREMs, PROMs clinician rated outcomes and assessment of the degree to which clinical indicators (reflected processes of clinical guidelines) were carried out. The assessments will take place at admission, discharge and every 3 months for up for 9 months. The design is a repeated measures design with evaluating the interaction effect between assessed levels of indicators (between subject effect) and level of change in the PREMs, PROMs clinician along the research trajectory (within subject effect).
Study: NCT03848442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Uptime' participation
Description: The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
Study: NCT05640804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTTQ Dasatinib tablet
Description: Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Chia Tai Tianqing Pharmaceutical Group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprycel Dasatinib tablet
Description: Sprycel Dasatinib tablet is an oral tyrosinekinase inhibitor produced by Bristol Myers Squibb.
Study: NCT03070444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTC retainer
Description: The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essix retainer maxilla
Description: The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
Study: NCT01960608

Intervention type: OTHER
Intervention: 24_hours_urine_sodium

Intervention type: OTHER
Intervention: 24_hours_urine_sodium
Study: NCT03070444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Essix retainer maxilla
Description: The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Essix retainer mandible
Description: The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alginate impression
Description: Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alginate impression
Description: Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A questionnaire is completed at the follow-up visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: A questionnaire is completed at the follow-up visits.
Study: NCT01595672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN69 hemofilter
Description: An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatments
Description: Patients receive conventional treatments recommended by guidelines only.
Study: NCT01135602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 50-300 mg/day Orally Twice per day
Study: NCT03829774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary Relief v 2.0
Description: The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
Study: NCT01319357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: orally 5 mg/d for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally for 6 weeks
Study: NCT02112006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine injected in the forearm
Description: Median, Ulnar, and Radial nerve blocks performed in the forearm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20-30ml of 0.5% bupivacaine.
Description: supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
Study: NCT01960608

Intervention type: OTHER
Intervention: 24_hours_urine_sodium
Study: NCT03532750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Particle
Description: 1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578.
Study: NCT02026284

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
Study: NCT00870350

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td5ap
Description: Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td1aP
Description: Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
Study: NCT00658411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferoxamine
Description: Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
Study: NCT02443792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicirc with tissue adhesive
Description: As above

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgical
Description: As above
Study: NCT02051439

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Valsava
Description: The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
Study: NCT01560143

Intervention type: DRUG
Group type: OTHER
Intervention: Tigecycline
Description: 100 mg IV as a single infusion over 30 minutes
Study: NCT01688544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10 mg for 7 days
Study: NCT00919438

Intervention type: DEVICE
Intervention: AVIVO™ Mobile Patient Management System
Description: Non Invasive monitoring device
Study: NCT01268566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion.
Study: NCT02744079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: 45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: 20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
Study: NCT01462019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions.
Study: NCT04415112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: A list of foods high consumption of vegetables, fruits, non-refined cereals, legumes and potatoes, moderate consumption of fish and poultry and low consumption of full fat dairies, red meat and its products and homemade sweets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: These children are forbidden to eat high-fat foods such as fried foods, butter, cream cheese, while foods such as fruits, vegetables (starchy and non-starch), cereals, poultry, lean meat and low-fat dairy products are allowed.
Study: NCT00451451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Study: NCT00462631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon
Description: Paclitaxel eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel eluting stent
Description: paclitaxel eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bare metal stent
Description: bare metal stent
Study: NCT02604056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit + Feedback
Description: Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit + Feedback
Description: Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit + Feedback + Educational Outreach
Description: The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home.
Study: NCT01225770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea
Description: Gargling three times daily for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: green tea
Description: Gargling three times daily for 90 days
Study: NCT00071578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy-Negative Emotion Focus
Description: 20 weekly sessions, 2 hours, group format

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group Psychotherapy- Self-Esteem Focus
Description: 20 weekly sessions, 2 hours, group format
Study: NCT01654627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenecure AMCA GBR Dental Membrane
Description: Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Gide® collagen membrane
Description: The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
Study: NCT00881101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
Study: NCT03608371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-246040
Description: oral capsule 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-246040
Description: oral capsule 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-246040
Description: oral capsule 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule matching BTRX-246040 40 mg capsule
Study: NCT05073640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxopurin
Description: Subjects will receive two capsules per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxopurin
Description: Subjects will receive two capsules per day.
Study: NCT02619669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
Study: NCT04204564

Intervention type: DEVICE
Intervention: pactlitaxel PAD device
Description: Peripheral vascular intervention on femoral-popliteal occlusive disease with paclitaxel and non-paclitaxel devices.
Study: NCT02619669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
Study: NCT05863338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NURSING FOLLOW-UP BY PHONE
Description: The training was carried out in the form of individual training and as a single session.The training,which lasted about 30 minutes,was carried out in the training room of the polyclinic with the support of Barco vision.In the training session,lecture,question-answer methods were used and at the end of the training session,a booklet containing the training content was given to the patients.The researcher phoned the patients once a week for 24 weeks,conveyed how they were doing,whether there was anything they wanted to ask or learn,and provided counseling to the patients in line with their needs.The next week's plan was also determined in the phone calls made in the following weeks.Patient follow-ups as stated were continued for 24 weeks.At the 12th and 24th weeks of the telephone nursing follow-up, the patients filled out the scales again.
Study: NCT04351997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord clamping
Description: Umbilical cord clamping after delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord clamping
Description: Umbilical cord clamping after delivery.
Study: NCT00585390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: * Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~* Docosahexaenoic acid fish oil concentrate at 1.6 grams

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil placebo
Description: Olive oil capsules, 8 capsules per day
Study: NCT01201538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT03464708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Powder form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose (placebo)
Description: Powder form
Study: NCT02514512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLC Tracking
Description: Treat patient with Non FDA approved MLC Tracking
Study: NCT00001262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Histidine
Study: NCT03532750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil
Description: Ruby or Interlock detachable coils
Study: NCT04366180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will received one placebo capsule per day during 2 months
Study: NCT03546829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 125 mg, 4x daily for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Precision hypofractionated radiation
Description: Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.